Business
Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
SAN JOSE, Calif., March 14, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., March 14, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. (\"Anixa\" or the \"Company\") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2024 Annual Meeting of Stockholders (the \"Meeting\") on Thursday, March 21, 2024 at 10:00 a.m. Pacific Time in a virtual format.\n\n \n \n \n \n \n \n\n \nFollowing the formal business and voting portion of the Meeting, Anixa Chairman and CEO Dr. Amit Kumar will deliver an investor presentation and corporate update, followed by a question-and-answer session. All interested parties may attend the Meeting.\nAll parties may access the Meeting online at www.virtualshareholdermeeting.com/ANIX2024.\nDuring his investor presentation, Dr. Kumar will discuss Anixa's portfolio of first-in-class oncology/immunology assets under development, with vaccines to prevent cancer and a CAR-T cell therapy to treat cancer. The Company's robust pipeline over the next 12 months includes three candidates based on two modalities, three indications, and two ongoing clinical trials.\nAbout Anixa Biosciences, Inc.Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The Company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against \"retired\" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.\nForward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the...